Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RADX vs OVID: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OVID Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–2 Matrix Metrics)

OVID Overall Winner 6-Pillar Tally: RADX 2 – 3 OVID (1 Tie) Matrix Metrics: RADX 2 – 7 OVID

As of Nov 20, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). RADX carries a Unified Composite Score of 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin), whereas OVID carries 52.3/100 (HOLD) at $2.20 (1.8x Forward P/E, -4693.7% operating margin).

  • Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (52.3/100 HOLD vs. RADX 41.1/100 SELL) and 1.04β · 97% Vol risk profile, whereas RADX leads top-line expansion (-36.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: RADX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RADX vs OVID
RADX NASDAQ
Radiopharm Theranostics Limited American Depositary Shares
Pharmaceutical Preparations
$0.63
-6.33% 1D
Market Cap $10.6M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 0.52β · 109% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.5%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.86 · SMA50: $1.15
OVID NASDAQ Head-to-Head Winner
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.20
-5.98% 1D
Market Cap $424.6M
TTM Revenue $1.5M
Forward P/E 1.8x
Beta / 30D Vol 1.04β · 97% Vol
Unified Composite Score
52.3 / 100 HOLD
Tech 30.0 Fund 48.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $2.49 · SMA50: $2.46

6-Pillar Scorecard Institutional Category Breakdown (RADX 2 – 3 OVID)

Columns: Metric · RADX · OVID
1. Valuation Multiples OVID
Forward P/E N/M 1.8x
Trailing P/E N/M 1.8x
PEG Ratio N/M N/M
EV / Revenue 0.8x N/M
2. Growth & Scale RADX
Revenue Growth (YoY) -36.9% -88.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M $1.5M
Market Cap $10.6M $424.6M
3. Profitability & Quality OVID
Gross Margin N/A 100.0%
Operating Margin -411.6% -4693.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -174.7% -35.4%
4. Balance Sheet & Cash Flow OVID
Cash Generation (TTM) -$50M EBITDA -$58M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.48 Book/Sh · -174.7% ROE $1.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RADX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 11.7% (<1st %ile)
Put/Call OI Skew Thin ADR Chain 0.18x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RADX (2) vs OVID (7)
Institutional Metric RADX OVID Criterion Row Edge
Market Capitalization
Scale
$10.6M $424.6M Larger Scale OVID
Trailing P/E Ratio
Valuation
N/M 1.8x Lower Multiple OVID
Forward P/E Ratio
Valuation
N/M 1.8x Lower Multiple OVID
Revenue Growth (YoY)
Growth
-36.9% -88.3% Higher Growth RADX
Operating Margin (TTM)
Profitability
-411.6% -4693.7% Higher Margin RADX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-174.7% -35.4% Higher ROE OVID
52-Week Range Position
Momentum
0% ($1–$16) 52% ($1–$3) Stronger Trend OVID
Beta / 30D Volatility
Risk Regime
0.52β · 109% Vol 1.04β · 97% Vol Lower Realized Risk OVID
Unified Institutional Score
Composite Signal
41.1 / 100 (SELL) 52.3 / 100 (HOLD) Higher Composite OVID
Trailing 12M Revenue (USD)
Operating Scale
$13M $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$50M EBITDA ($1.48 Book/Sh · -174.7% ROE) -$58M ($1.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OVID +26.47 pp
RADX: -33.64% · OVID: -7.17%
3M Horizon OVID +52.17 pp
RADX: -74.16% · OVID: -21.99%
6M Horizon OVID +78.29 pp
RADX: -86.24% · OVID: -7.95%
1Y Horizon OVID +158.23 pp
RADX: -86.35% · OVID: +71.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RADX vs OVID. Trailing 12-month operating profitability (RADX -411.6% vs OVID -4693.7%) and valuation multiples (RADX N/M vs OVID 1.8x Forward P/E) are benchmarked directly in Pillar 4 below.

RADX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross MarginN/A
Op. Margin-411.6%
ROE / Fwd P/E-174.7% · N/M
OVID ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.5M
Gross Margin100.0%
Op. Margin-4693.7%
ROE / Fwd P/E-35.4% · 1.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RADX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RADX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OVID BREAKDOWN
154d in phase · OBV DISTRIBUTION
Current IV 11.7%
IV Percentile <1st %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OVID Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RADX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.6M market capitalization and -411.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OVID Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $424.6M market capitalization and -4693.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RADX vs OVID Key Questions & Quantitative Answers

As of Nov 20, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). RADX carries a Unified Composite Score of 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin), whereas OVID carries 52.3/100 (HOLD) at $2.20 (1.8x Forward P/E, -4693.7% operating margin). Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (52.3/100 HOLD vs. RADX 41.1/100 SELL) and 1.04β · 97% Vol risk profile, whereas RADX leads top-line expansion (-36.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RADX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RADX leads the Growth & Scale pillar: RADX posts -36.9% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (N/A gross margin, -411.6% operating margin), compared with OVID at -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin). On trailing 12-month operating scale, RADX generates $13M in USD-normalized revenue versus $1.5M for OVID. In operating R&D and SG&A reinvestment, RADX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OVID.

OVID screens cheaper on headline valuation multiples. RADX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin), whereas OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RADX (-174.7% ROE) versus OVID (-35.4% ROE) capital efficiency.

In options market volatility and institutional positioning, RADX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.52β · 109% Vol realized risk). By comparison, OVID carries 11.7% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.04β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.